These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 2785582)
1. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. Brunetti A; Berg G; Di Chiro G; Cohen RM; Yarchoan R; Pizzo PA; Broder S; Eddy J; Fulham MJ; Finn RD J Nucl Med; 1989 May; 30(5):581-90. PubMed ID: 2785582 [TBL] [Abstract][Full Text] [Related]
2. [Cerebral glucose metabolism in dementia (PET-FDG study)]. Hatazawa J; Itoh M; Matsuzawa T Rinsho Hoshasen; 1989 Oct; 34(11):1343-8. PubMed ID: 2601096 [TBL] [Abstract][Full Text] [Related]
3. [F-18 FDG PET in dementia]. Ichiya Y Rinsho Hoshasen; 1989 Oct; 34(11):1337-41. PubMed ID: 2601095 [TBL] [Abstract][Full Text] [Related]
4. The metabolic pathology of the AIDS dementia complex. Rottenberg DA; Moeller JR; Strother SC; Sidtis JJ; Navia BA; Dhawan V; Ginos JZ; Price RW Ann Neurol; 1987 Dec; 22(6):700-6. PubMed ID: 3501695 [TBL] [Abstract][Full Text] [Related]
5. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Benson DF; Kuhl DE; Hawkins RA; Phelps ME; Cummings JL; Tsai SY Arch Neurol; 1983 Nov; 40(12):711-4. PubMed ID: 6605139 [TBL] [Abstract][Full Text] [Related]
6. Functional brain imaging in HIV-1-infected children born to seropositive mothers. Depas G; Chiron C; Tardieu M; Nuttin C; Blanche S; Raynaud C; Syrota A J Nucl Med; 1995 Dec; 36(12):2169-74. PubMed ID: 8523099 [TBL] [Abstract][Full Text] [Related]
7. Characteristics of cerebral glucose utilization in dementia. Matsuzawa T; Matsui H; Meguro K; Ueda M; Yamada K; Yamaguchi T; Itoh M; Hatazawa J; Kinomura S Sci Rep Res Inst Tohoku Univ Med; 1990 Dec; 37(1-4):11-21. PubMed ID: 2103655 [TBL] [Abstract][Full Text] [Related]
8. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. Rottenberg DA; Sidtis JJ; Strother SC; Schaper KA; Anderson JR; Nelson MJ; Price RW J Nucl Med; 1996 Jul; 37(7):1133-41. PubMed ID: 8965184 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of the different methods to calculate cerebral glucose utilization using F-18 FDG and PET]. Kuwabara Y; Ichiya Y; Otsuka M; Tahara T; Miyake Y; Uehara S; Yoshimura A; Masuda K Kaku Igaku; 1989 Mar; 26(3):459-63. PubMed ID: 2787439 [No Abstract] [Full Text] [Related]
10. Oral 18F-fluoro-2-deoxyglucose for primate PET studies without behavioral restraint: demonstration of principle. Martinez ZA; Colgan M; Baxter LR; Quintana J; Siegel S; Chatziioannou A; Cherry SR; Mazziotta JC; Phelps ME Am J Primatol; 1997; 42(3):215-24. PubMed ID: 9209586 [TBL] [Abstract][Full Text] [Related]
11. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. Farkas T; Ferris SH; Wolf AP; De Leon MJ; Christman DR; Reisberg B; Alavi A; Fowler JS; George AE; Reivich M Am J Psychiatry; 1982 Mar; 139(3):352-3. PubMed ID: 6977276 [No Abstract] [Full Text] [Related]
12. Effects of percent thresholding on the extraction of [18F]fluorodeoxyglucose positron emission tomographic region-of-interest data. Rottenberg DA; Moeller JR; Strother SC; Dhawan V; Sergi ML J Cereb Blood Flow Metab; 1991 Mar; 11(2):A83-8. PubMed ID: 1997493 [TBL] [Abstract][Full Text] [Related]
13. Reproducibility of cerebral glucose utilization measured by PET and the [18F]-2-fluoro-2-deoxy-d-glucose method in resting, healthy human subjects. Maquet P; Dive D; Salmon E; von Frenckel R; Franck G Eur J Nucl Med; 1990; 16(4-6):267-73. PubMed ID: 2351175 [TBL] [Abstract][Full Text] [Related]
15. Peptide T and glucose metabolism in AIDS dementia complex. Villemagne VL; Phillips RL; Liu X; Gilson SF; Dannals RF; Wong DF; Harris PJ; Ruff M; Pert C; Bridge P; London ED J Nucl Med; 1996 Jul; 37(7):1177-80. PubMed ID: 8965193 [TBL] [Abstract][Full Text] [Related]
16. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. Schmidt KC; Lucignani G; Sokoloff L J Nucl Med; 1996 Feb; 37(2):394-9. PubMed ID: 8667082 [No Abstract] [Full Text] [Related]
17. Positron emission tomography findings in dementia disorders: contributions to differential diagnosis and objectivizing of therapeutic effects. Heiss WD; Herholz K; Pawlik G; Hebold I; Klinkhammer P; Szelies B Keio J Med; 1989 Jun; 38(2):111-35. PubMed ID: 2674513 [TBL] [Abstract][Full Text] [Related]
18. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. Pizzo PA; Eddy J; Falloon J; Balis FM; Murphy RF; Moss H; Wolters P; Brouwers P; Jarosinski P; Rubin M N Engl J Med; 1988 Oct; 319(14):889-96. PubMed ID: 3166511 [TBL] [Abstract][Full Text] [Related]
19. Imaging local brain function with emission computed tomography. Kuhl DE Radiology; 1984 Mar; 150(3):625-31. PubMed ID: 6607481 [TBL] [Abstract][Full Text] [Related]
20. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. Friedland RP; Budinger TF; Ganz E; Yano Y; Mathis CA; Koss B; Ober BA; Huesman RH; Derenzo SE J Comput Assist Tomogr; 1983 Aug; 7(4):590-8. PubMed ID: 6602819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]